• Slider Image
  • Slider Image
  • Slider Image

In the Press


February 24, 2016

Emphasizing Collaboration at a Pivotal Moment in Cancer Research: Ida Deichaite's opinion article in Xconomy San Diego features the 12th Moores Cancer Center Industry/Academic Translational Oncology Symposiumn on February 25 and the current cancer therapy landscape.
   » Xconomy Opinion Article


July 8, 2015

Researchers at UC San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. MCC Investigator Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team.
   » UC San Diego Health System Press Release
   » San Diego Union Tribune article


February 22, 2015

CIRM's Klein proposes $100B biomed program: Bob Klein describes his vision of how to increase biomedical funding to hasten discovery and commercialization of disease treatments. He spoke Thursday, Feb. 19, at the annual UCSD Moores Cancer Center symposium.
   » San Diego Union Tribune article


February 21, 2015

Fighting patient, fighting doctor: : Patient Theresa Blanda speaks about her experience battling cancer with the help of Moores Cancer Center Investigator Dr. Catriona Jamieson, at the 11th annual Industry/Academia Translational Oncology Symposium.
   » San Diego Union Tribune article


February 19, 2015

Katherine Connor from the San Diego Daily Transcript reports on the new funding paradigm needed for scientific research: Some of the nation’s top oncology researchers and private companies in the cancer space met at the University of California, San Diego Moores Cancer Center Thursday for the 11th annual Industry/Academic Translational Oncology Symposium.
   » San Diego Daily Transcript article


February 13, 2015

The Union-Tribune published an opinion editorial by Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD, entitled "Finding Ways to create cancer-killing swords". The op-ed features the upcoming 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium on February 19, and the ongoing collaborations at MCC.
   » Union Tribune Op-ed



» More Press




Stay Updated





2016 Symposium: Save the Date!


Our 12th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium will be held on Thursday February 25, 2016. Learn more about the symposium and presentation topics here.

Keynote Speaker
Polyvalent vaccines targeting oncogenic driver pathways

Nora Disis, MD

Adjunct Professor of Pathology and Obstetrics and Gynecology
Fred Hutchinson Cancer Research Center
Associate Dean for Translational Science
University of Washington School of Medicine

Keynote Speaker
Molecular diversity of human breast cancer: biologic and therapeutic implications

Dennis Slamon, MD, PhD

Director, Clinical/Translational Research
UCLA Jonsson Comprehensive Cancer Center

Please note: Additional speakers will be announced as they are confirmed.


Translational studies of KTN3379, a novel anti-ErbB3 antibody

Diego Alvarado, PhD

Associate Director of Research
Kolltan Pharmaceuticals

Immuno-Oncology: Rational combination therapy

Chris Boshoff, MD, PhD

Vice President, Early Development, Translational and Immuno-Oncology
Pfizer, Inc.

Compound development of LADD therapeutics in prostate and lung cancer

Robert Charnas, PhD

Compound Development Team Leader
Janssen R&D

Lung cancer KRAS addiction is reversed by disrupting an integrin/lectin membrane complex

David Cheresh, PhD

UC San Diego Moores Cancer Center

The role of MET exon14 deletion mutations as driver oncogenes in patients with NSCLC and therapeutic intervention with the prototype MET inhibitor glesatinib

Jamie Christensen, PhD

Chief Scientific Officer
Mirati Therapeutics

Overview

Ezra Cohen, MD

UC San Diego Moores Cancer Center

Monitoring daily dynamics of early tumor response to targeted therapy in lung cancer

Hatim Husain, MD

UC San Diego Moores Cancer Center

Mark Erlander, PhD

Chief Scientific Officer
Trovagene

The role of the microenvironment in modulating tumor angiogenesis

Napoleone Ferrara, MD

UC San Diego Moores Cancer Center

Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic

J. Silvio Gutkind, PhD

UC San Diego Moores Cancer Center

Detection and targeting of malignant niche mediated cancer stem cell generation

Catriona Jamieson, MD, PhD

UC San Diego Moores Cancer Center

Bone microenvironment and drug resistance

Christina Jamieson, PhD

UC San Diego Moores Cancer Center

Anti-cancer therapies derived from human pluripotent stem cells

Dan Kaufman, MD, PhD

UC San Diego Moores Cancer Center

In the wake of homologous repair deficiency: Identifying PARP inhibitor responsive patients

Keith Mikule, PhD

Director, Preclinical Research
TESARO

Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations

Deborah Morosini, MD

Vice President, Clinical Affairs and Patient Engagement
Foundation Medicine

Partnering with patients to accelerate the pace of biomedical research

Corrie Painter, PhD

Associate Director of Operations and Scientific Outreach
Broad Institute of MIT and Harvard

Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy

Tony Polverino, PhD

Vice President, Research
Kite Pharma

Anti-ErbB3 therapies – what do we know to date

Birgit Schoeberl, PhD

SVP, Head of Discovery
Merrimack

Towards personalized immunotherapy of HNSCC

Stephen Schoenberger, PhD

Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology
Head of Cancer Vaccines, Human Longevity Inc.

Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody

Victoria Smith, PhD

Senior Director, Biology
Gilead Sciences




2015 Symposium Slideshow



Thank you to all that came and participated in the 2015 Symposium - we hope you enjoy the memories!



2015 Symposium:


Our 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium took place on Thursday February 19, 2015.

Featured talks:

Keynote Presentation: Imatinib as a Paradigm of Molecularly Targeted Cancer Therapies


Brian Druker, MD
OHSU Knight Cancer Institute


Duane Roth Award


Presented by Rep. Scott Peters, Congressman
Awarded to Brian Druker, MD, OHSU Knight Cancer Institute



Keynote Presentation: Cancer Genomics: Turning Discovery into Translation


Elaine Mardis, PhD
The Genome Institute
Washington University School of Medicine



Finding the Money to Fund Translational Research


Rep. Scott Peters, Congressman
Bob Klein, Klein Financial Corporation



Take a look at the speaker bios and more featured talks.



2014 Translational Oncology Symposium

A decade of fostering collaborations, fueling innovation & saving lives



San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Heather Clark, a patient of Moores Cancer Center, along with Ida Deichaite, Director of Industry Relations & Symposium Organizer, in a video report about the I-SPY Clinical Trial and Symposium. The I-SPY Clinical Trial is lead by Symposium Keynote Speaker and Principle Investigator Laura Esserman, MD, MBA. For the video, see below.



The article is available here.

  • Xconomy’s San Diego Life Sciences Roundup included Bob Klein’s Proposal presented at the Moores Cancer Center Symposium, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016.
         » Read Here
  • Xconomy's San Diego Life Sciences Roundup also included the Moores Cancer Center Symposium and Laura Esserman's acceptance of the Duane Roth Award.
         » Read Here
  • The San Diego Daily Transcript published an article about Dr. Esserman's acceptance of the Duane Roth Award and the Symposium.
         » Read Here
  • The San Diego Union Tribune wrote an article on the Symposium, namely the iSPY Trial and patient from the trial, San Diego Resident Heather Clark.
         » Read Here
  • Symposium Speaker Bob Klein was featured in a San Diego Union Tribune article, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016, presented at the Moores Cancer Center Symposium.
         » Read Here


Our Symposium Page




9th Symposium Featured on San Diego ABC 10 News




San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Linda Lowe, a patient of Moores Cancer Center Investigator Dr. Catriona Jamieson, along with Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD , in a video report from the 6PM News on April 11 covering the successful 9th Industry/Academia Translational Oncology Symposium.

More In the Press